Agenda
• 3:00-3:30 PM Networking, Registration & Tour
• 3:30-5:00 PM Expert Panel
• 5:00-6:30 PM Networking Reception

Although VC's are a traditional source of funds, there are many opportunities for financing that can get your company to where you need it to be. You just need to know the right people.

Join our panel to hear from private wealthy individuals, government granting agencies, foundations, angels and VCs who have opportunities for you to fund your company.

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception and Ipod raffle.

Send to Outlook»

Speakers
• Kurt A. Henry, MD, Biological Defense Research Directorate, Naval Medical Research Center
• Ted McCluskey, MD, PhD, Board Member, Sand Hill Angels; & CMO, Aviir, Inc. Click Here for Bio»
• JC Simbana, Vice President, Venture Banking, Square 1 Bank Click Here for Bio»
• Adam S. Bristol, PhD, Portfolio Manager & Investment Researcher, Biotechnology Value Fund, L.P. Click Here for Bio»
• Erez Levy, Managing Director, International Group, TriplePoint Capital Click Here for Bio»
• Guy Miller MD, PhD, Chairman, CEO, Edison Pharmaceuticals Click Here for Bio»
• Sohini Chowdhury, Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research Click Here for Bio»
• Jo Anne Goodnight, NIH SBIR/STTR Program Coordinator, Division of Special Programs Director, Office of Extramural Programs, OER, NIH, DHHS, National Institutes of Health Click Here for Bio»
• Lead Facilitator: Gregory W. Heibel, Partner, Corporate Group, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP Click Here for Bio»

Cost & Registration
• Panel + Networking Reception:
     ° Regular Price: $40
     ° Partners' Network: $30
     ° BioCenter Members: Free
• Networking Reception only: $20
• On-site Registration, if space allows: add $10 to the above
This event is typically sold out, therefore please register early to secure your spot.

Save time and money: register to more 2008 Panels!
Sep. 18: Overcoming M&A Challenges
Dec. 11: Holiday Celebration & Trends In Financing Investor Panel


Speakers Bios

Ted McCluskey, MD, PhD, Board Member, Sand Hill Angels; & CMO, Aviir, Inc.
Ted McCluskey MD/PhD, is a co-chair of membership at Sand Hill Angels. He is currently at Scios, Inc. (a Johnson & Johnson company) in Mountain View where he works on the clinical development of Scios' lead biopharmaceutical, Natrecor. In addition, in his more than three years at Scios, Ted has overseen clinical development of VEGF in pre-eclampsia, participated in cardiovascular business development assessments and worked on internal strategy and leadership projects.
Prior to Scios, Ted was at Genentech for 8 years, overseeing clinical research on cardiovascular applications for TNKase, Bosentan, CathFlo Activase and most recently for the recently approved anti-angiogenic ophthalmic agent Lucentis. He led the clinical development for the cardiovascular application of VEGF (vascular endothelial growth factor) by direct intra-coronary injection. He has had extensive experience in both in-licensing and out-licensing projects. While at Genentech, he received additional training in Finance, Marketing and Management (Berkeley) and in Leadership and Strategy at an executive program at Harvard Business School.
Ted was trained as an interventional cardiologist (Cleveland Clinic) and served for several years on the faculty of the University of Cincinnati. Prior molecular biology and clinical cardiology training were at UCSF. His medicine residency was at Washington University in St. Louis as were his MD and PhD (Pharmacology). His undergraduate degree was in chemistry (with research honors) from Stanford.
JC Simbana, Vice President, Venture Banking, Square 1 Bank
JC is a Vice President at Square 1 Bank, with more than ten years of experience in financial services. JC leads Square 1 Bank’s life science practice in Northern California, where he focuses on strengthening relationships with select venture capital firms and providing venture-backed companies with banking and debt financing solutions.
Before joining Square 1 Bank, JC was a venture banker with Comerica’s Technology & Life Science Division, where he focused on working with biotech and medical device companies. Prior to venture banking, JC spent five years working as an equity analyst – most recently for Moors & Cabot, Inc.’s Technology Research Group, initiating coverage and publishing research reports. The combination of his experience as a venture banker and institutional equity analyst provide him with an understanding of a client’s needs from seed-stage to IPO.
Adam S. Bristol, PhD, Portfolio Manager & Investment Researcher, Biotechnology Value Fund, L.P.
Dr. Bristol is a portfolio manager and investment researcher at Biotechnology Value Fund, a dedicated life science investment fund based in San Francisco, CA. He has served as a start-up mentor for NIH's Commercialization Assistance Program through LARTA and for UC-Davis's Environmental Health Entrepreneurship Academy. He obtained his PhD in cellular and systems neuroscience from Yale University and did his postdoctoral training at Stanford University's School of Medicine.
The Biotechnology Value Fund (BVF) is a dedicated life science private investment fund. Started in 1993, BVF currently has over $600M in assets. Our investments focus on seed-stage, pre-clinical companies developing breakthrough drugs and drug discovery technologies that have the potential to do substantial social good. Our experience in corporate development allows us to work closely with companies and help them reach preclinical milestones and maximize growth potential with an emphasis on attracting non-dilutive capital. Our current family of investments includes Acumen Pharmaceuticals, Airmid, Biotica, CFD Therapeutics, Keel Pharmaceuticals, Mendel Biotechnologies, and Viriome.
Erez Levy, Managing Director, International Group, TriplePoint Capital
Erez Levy is a Managing Director at TriplePoint Capital, a leading global specialty finance company with an unsurpassed capacity to transact loans and leases with leading high-growth companies throughout their lifespan.
Prior to joining TriplePoint Capital Erez served as a senior investment banker at JPMorgan’s technology group in San Francisco, where he worked with many leading technology and high growth companies, raising capital and providing advice on mergers and acquisitions.
Prior to JPMorgan, Erez was at Hambrecht & Quist (H&Q), a leading technology and life-sciences investment bank where he worked with many of the firms clients. At H&Q, Erez also led several of the firm’s investments in leading technology and high-growth companies.
In addition, Erez was instrumental in building both H&Q’s and JPMorgan’s international technology investment banking practices.
Guy Miller MD, PhD, Chairman, CEO, Edison Pharmaceuticals
Guy Miller, MD, PhD, is the Chairman and Chief Executive Officer of Edison Pharmaceuticals. He holds a clinical faculty appointment at Stanford University School of Medicine/PAVAMC, in medical-surgical critical care and is an Adjunct Professor, University of North Carolina, School of Public Health. Prior to Edison, he founded Galileo Pharmaceuticals, and was its Chairman and CEO from 1995-2005. Dr. Miller completed a surgical internship at the University of Chicago and residency and fellowship in anesthesiology & critical care medicine at Johns Hopkins, where he was an Assistant Professor until 1995.
Edison has obtained substantial non-dilutive peer-reviewed grant support to advance both its pre-clinical and clinical initiatives from foundations including the Muscular Dystrophy Association, Friedreich's Ataxia Research Alliance, and Seek A Miracle. The company closed Series A Preferred Stock Offering in November 2005, and recently announced a Series B Financing led by Mr. Carl Berg, Berg & Berg Enterprises, LLC. New investors include John W. Marriott, III, President and CEO of JWM, LP, and JWM Family Enterprises.
Sohini Chowdhury, Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research
Sohini Chowdhury is the point person for The Michael J. Fox Foundation for Parkinson's Research on all industry activity. Ms. Chowdhury joined the Foundation after spending five years at the World Economic Forum in Geneva, Switzerland. As the Senior Community Manager of the Forum's Technology Pioneers program, she was responsible for annually selecting and integrating innovative biotech, energy and IT technology companies into Forum activities. Ms. Chowdhury also worked directly for the Forum's CEO, acting as his liaison with key Forum stakeholders and overseeing several in-house projects. Ms. Chowdhury graduated with an MA from Georgetown University, and holds a BA in International Studies from Vassar College.
The path from research discovery to the creation of a new treatment is often an extremely long one. The average time for the development of a new central nervous system treatment is currently 13 years. The Michael J. Fox Foundation is helping to speed up drug development for PD with innovative strategies that identify roadblocks along the therapeutic development pipeline. By sharing the risk of drug development with academic and industry researchers alike, we hope to increase the movement of new treatments into the clinic.
The Michael J. Fox Foundation's unique value-add lies not in any single investment, but in pursuing multiple promising initiatives at once. As a private funder, with a comprehensive view of the field and proactive management of the grants in our portfolio, MJFF is ideally positioned to identify opportunities and create synergies all along the continuum from basic to clinical research. We do this in service of one principal goal: systematically shepherding basic discoveries and translational advances toward meaningful clinical outcomes. All potential MJFF investments are evaluated against their promise to return meaningful progress in critical areas of the therapeutics development pipeline.

Jo Anne Goodnight, NIH SBIR/STTR Program Coordinator, Division of Special Programs Director, Office of Extramural Programs, OER, NIH, DHHS, National Institutes of Health
In March 1999, Ms. Jo Anne Goodnight became the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program Coordinator of the National Institutes of Health (NIH) and the Department of Health and Human Services (DHHS) Public Health Service. She also serves as the Director for the Division of Special Programs in the Office of Extramural Research (OER).
Ms. Goodnight has more than 25 years of Government service. She has held positions in the U.S. Department of Agriculture (USDA), the Food and Drug Administration, and now the NIH where she has been a part of the National Cancer Institute (NCI) Intramural Research Program and the NCI Extramural Research Program. As an intramural research scientist (1989–1994), she published over 20 studies about the selective involvement of Protein Kinase C in differentiation and neoplastic transformation. In 1994, she became a Program Director for SBIR/STTR grants that supported studies in the field of cancer biology, cancer genetics, and cancer immunology. She also served as the NCI’s SBIR/STTR Program Policy Coordinator and Special Assistant to the Director, Division of Cancer Biology.
Ms. Goodnight leads NIH’s efforts to better manage and coordinate the NIH SBIR/STTR Programs. She was intimately involved in the development and implementation of the NIH SBIR/STTR Fast-Track Program, SBIR/STTR Phase II Competing Renewal Awards, NIH Technical/Commercialization Assistance Programs, and the NIH Pipeline to Partnerships initiative. She continues to develop other programs that assist the small business community in commercialization of their technologies.
Ms. Goodnight has been an invited speaker at hundreds of SBIR/STTR Conferences. She also has provided written and oral testimony at Congressional hearings related to the reauthorization of the SBIR and STTR Programs. Her contributions to the SBIR/STTR programs and passion for helping small businesses to be successful in these programs have been acknowledged through several national awards including NIH Director’s Awards, NIH Merit Awards, and the Small Business Administration Tibbetts Award.
Ms. Goodnight received a Bachelor of Science degree in Microbiology from Virginia Tech in 1983. Go Hokies. We Will Not Forget.
Lead Facilitator: Gregory W. Heibel, Partner, Corporate Group, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP
Greg Heibel, a partner in the Silicon Valley office, is a member of the Emerging Companies practice group, which advises emerging and public technology companies, venture capital firms and other technology investors. Mr. Heibel’s practice includes the formation, financing and general corporate counseling of rapidly growing technology companies; the representation of venture capital firms and other investors in private and public offerings, as well as other complex transactions related to high growth companies. Mr. Heibel has completed hundreds of venture capital financings, mergers, acquisitions and licensing transactions for clients in the networking, wireless, Internet, software, life sciences and consumer industries. Additionally, Mr. Heibel has represented numerous Nasdaq listed companies in their public offering, mergers and acquisitions and ongoing corporate governance needs, including Foundry Networks, Virage Networks, Adeza, Laserscope, Intellisync and Preview Systems.

Venue
Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Menlo Park, CA 94025-1015
Click here for Venue Directions»